Bukari Abdallah, Wali Eisha, Deshmukh Amrish, Aziz Zaid, Broman Michael, Beaser Andrew, Upadhyay Gaurav, Nayak Hemal, Tung Roderick, Ozcan Cevher
Department of Medicine, Section of Cardiology, Center for Arrhythmia Care, Heart and Vascular Center, University of Chicago Medicine Pritzker School of Medicine, 5841 S. Maryland Avenue, MC 6092, Chicago, IL, 60637, USA.
J Interv Card Electrophysiol. 2018 Dec;53(3):365-371. doi: 10.1007/s10840-018-0463-7. Epub 2018 Oct 6.
This study aimed to determine the incidence, prevalence, and predictors of atrial arrhythmias (AAs) in patients with symptomatic sinus node dysfunction (SND) who required permanent pacemaker implantation. Also, we evaluated the impact of atrial pacing (AP) on AAs.
All consecutive patients who underwent pacemaker implantation from 2005 to 2011 were included. Atrial fibrillation (AF), atrial flutter (AFL), atrial tachycardia (AT), and AV nodal reentrant tachycardia (AVNRT) were detected via pacemaker interrogation and clinical documentation.
The study group included 322 patients (44% male) with mean age 68.8 ± 15 years and followed for an average of 5.6 ± 2.2 years (median 5.7 years). Overall, 61.8% were found to have any AA at follow-up. Individual prevalence of AAs was high as follows: AF 43.5%, AFL 6.5%, AT 25%, and AVNRT 6.8%. AF was documented in 23% of patients (n = 74) prior to pacemaker; among those, 15% (n = 11) had no recurrence of AF with average AP of 74%. The incidence of new-onset AF after pacemaker was 15.8%. In subgroup analysis, prevalence of AF was increased by 16% with high rate of AP (81-100%) and 17% with lower rate of AP (0-20%). Incidence of new-onset AF was not affected by AP. Diabetes, hypertension, and left atrial enlargement were predictors of AAs. White men and women had higher prevalence of AF.
AAs are highly prevalent in SND, particularly in white patients. Paroxysmal AF is suppressed with AP in minority, but there is no impact of AP on new-onset AF. Patients with diabetes, hypertension, and dilated atria must be monitored closely for early detection of AAs.
本研究旨在确定有症状的窦房结功能障碍(SND)且需要植入永久起搏器的患者中心房心律失常(AA)的发生率、患病率及预测因素。此外,我们评估了心房起搏(AP)对AA的影响。
纳入2005年至2011年期间所有连续接受起搏器植入的患者。通过起搏器问询和临床记录检测心房颤动(AF)、心房扑动(AFL)、房性心动过速(AT)和房室结折返性心动过速(AVNRT)。
研究组包括322例患者(44%为男性),平均年龄68.8±15岁,平均随访5.6±2.2年(中位数5.7年)。总体而言,随访时发现61.8%的患者有任何AA。AA的个体患病率较高,如下所示:AF 43.5%,AFL 6.5%,AT 25%,AVNRT 6.8%。起搏器植入前23%的患者(n = 74)记录有AF;其中,15%(n = 11)的患者AF未复发,平均AP率为74%。起搏器植入后新发AF的发生率为15.8%。亚组分析中,AP率高(81 - 100%)时AF患病率增加16%,AP率低(0 - 20%)时增加17%。新发AF的发生率不受AP影响。糖尿病、高血压和左心房扩大是AA的预测因素。白种男性和女性AF患病率较高。
AA在SND中非常普遍,尤其是在白种患者中。少数情况下阵发性AF可被AP抑制,但AP对新发AF无影响。必须密切监测糖尿病、高血压和心房扩大的患者,以便早期发现AA。